VisEn Medical, Inc.

VisEn Medical Raises $5.0 Million in Expanded Series B Financing

VisEn Medical Raises $5.0 Million in Expanded Series B Financing

April 18, 2008

Woburn, MA, April 18, 2008 -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging, today announced the expansion of its Series B financing. Merck Capital Ventures and Flagship Ventures co-led this $5.0 million expansion of the Series B round, which initially raised $7 million in November 2007, bringing the total Series B financing amount to $12.0 million. VisEn will use the additional financing to further advance its proprietary fluorescence in vivo imaging product pipelines, and to expand its commercial applications and customer support of its marketed products worldwide.

Resolvyx Pharmaceuticals, Inc.

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders

April 22, 2008

BEDFORD, Mass.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the appointment of Timothy J. Barberich and George M. Milne, Jr., Ph.D, to Resolvyx's Board of Directors. Resolvyx is focused on developing drugs based on resolvins, a recently discovered family of naturally-occurring, small molecule lipid mediators that actively resolve inflammation and can be targeted to treat a wide range of diseases, including asthma, cardiovascular disease and multiple eye diseases.

Resolvyx Pharmaceuticals, Inc.

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

April 22, 2008

Company Advancing Resolvin Therapeutics to Initiate Human Clinical Trials in 2008

Black Duck Software, Inc.

Black Duck Software Acquires Software Code Search Leader Koders

Black Duck Software Acquires Software Code Search Leader Koders

April 28, 2008

WALTHAM, Mass. - (Business Wire) Black Duck Software, the leading global provider of products and services for accelerating software development through the managed use of open source software, today announced it has acquired the assets of Koders as well as the company’s popular on-line search engine for open source software and other web-downloadable code. Black Duck will improve the free online search site and incorporate Koders’ search capability into its highly successful open source product portfolio.

Helicos BioSciences Corporation

Helicos BioSciences Reports Q1 2008 Financial Results

Helicos BioSciences Reports Q1 2008 Financial Results

April 29, 2008

CAMBRIDGE, Mass., Apr 29, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its financial results for the quarter ended March 31, 2008.

Concert Pharmaceuticals, Inc.

CoNCERT Pharmaceuticals Raises $37 Million in Series C Financing

CoNCERT Pharmaceuticals Raises $37 Million in Series C Financing

April 30, 2008

Broad Syndicate of New and Existing Investors

Selventa

Genstruct and Sirtris Pharmaceuticals Win Bio-IT World’s Best Practices Award

Genstruct and Sirtris Pharmaceuticals Win Bio-IT World’s Best Practices Award

April 30, 2008

Causal Network Modeling Provides Powerful Approach to Modeling Complex Biological Systems for Type 2 Diabetes

Mascoma Corporation

GM and Mascoma Enter into Biofuels Relationship

GM and Mascoma Enter into Biofuels Relationship

May 1, 2008

Automaker to Help Speed One-Step Cellulose-to-Fuels Process to Market

WASHINGTON, May 1 – General Motors Corp. and Mascoma Corp. today announced a strategic relationship to develop cellulosic ethanol focused on Mascoma’s single-step biochemical conversion of non-grain biomass into low-carbon alternative fuels to help address increasing energy demand.

Mascoma Corporation

Mascoma Corporation Raises $61 Million in Third Round of Funding

Mascoma Corporation Raises $61 Million in Third Round of Funding

May 6, 2008

Marathon Oil Corporation Leads Round

VisEn Medical, Inc.

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials Of Novel Fluorescence Molecular Imaging Technologies

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials Of Novel Fluorescence Molecular Imaging Technologies

June 16, 2008

Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems

Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer